Zoledronic Acid Dosing Interval for Metastatic Cancer Reply

被引：2
|
作者：
Himelstein, Andrew L. [1 ]
Loprinzi, Charles L. [2 ]
Shapiro, Charles L. [3 ]
机构：
[1] Helen F Graham Canc Ctr & Res Inst, 4701 Ogletown Stanton Rd,Ste 3400, Newark, DE 19713 USA
[2] Mayo Clin, Rochester, MN USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 317卷 / 14期
关键词：
BONE METASTASES;
D O I：
10.1001/jama.2017.2566
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1478 / 1478
页数：1
相关论文
共 50 条
  • [41] Estramustine, zoledronic acid and weekly docetaxel in metastatic androgen independent prostate cancer (MAIP).
    Nasr, FL
    Chahine, GY
    Moukaddem, WT
    Farhat, FS
    Tueini, EA
    Kattan, JG
    Dagher, JE
    Younes, FC
    Ghosn, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 440S - 440S
  • [42] Zoledronic acid benefits in cancer
    不详
    EJHP PRACTICE, 2008, 14 (05): : 15 - 15
  • [43] Metastatic Inflammatory Breast Cancer Associated With Multicentric Reticulohistiocytosis Successfully Treated With Zoledronic Acid
    Varilla, Vincent
    Taxel, Pamela
    Tannenbaum, Susan
    CLINICAL BREAST CANCER, 2016, 16 (06) : E203 - E207
  • [44] Efficacy of continuing zoledronic acid beyond 24 months in metastatic prostate cancer.
    Ferreira, A.
    Mauricio, M. C.
    Azevedo, L. F.
    Teixeira-Pinto, A.
    Sousa, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
    Himelstein, Andrew L.
    Foster, Jared C.
    Khatcheressian, James L.
    Roberts, John D.
    Seisler, Drew K.
    Novotny, Paul J.
    Qin, Rui
    Go, Ronald S.
    Grubbs, Stephen S.
    O'Connor, Tracey
    Velasco, Mario R., Jr.
    Weckstein, Douglas
    O'Mara, Ann
    Loprinzi, Charles L.
    Shapiro, Charles L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 48 - 58
  • [46] Improving documentation of zoledronic acid interval in ambulatory oncology patients
    Dandawate, Tanvi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 323 - 323
  • [47] Zoledronic acid in metastatic castrate-sensitive prostate cancer: A state-of-the-art review
    Damaj, Nahed
    Najdi, Tala
    Seif, Samah
    Nakouzi, Nicolas
    Kattan, Joseph
    JOURNAL OF BONE ONCOLOGY, 2025, 51
  • [48] The improvement of overall survivals in patients with metastatic breast cancer by zoledronic acid: The assessment of the real world
    Watanabe, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S284 - S285
  • [49] A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
    Zaghloul, Mohamed S.
    Boutrus, Rimoun
    El-Hossieny, Hisham
    Kader, Yasser Abdel
    El-Attar, Inas
    Nazmy, Mohamed
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (04) : 382 - 389
  • [50] Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial
    Carteni, Giacomo
    Bordonaro, Roberto
    Giotta, Francesco
    Lorusso, Vito
    Scalone, Simona
    Vinaccia, Vincenza
    Rondena, Roberta
    Amadori, Dino
    ONCOLOGIST, 2006, 11 (07): : 841 - 848
12345